首页> 外文期刊>Expert opinion on investigational drugs >Lucinactant:a novel synthetic surfactant for the treatment of respiratory distress syndrome
【24h】

Lucinactant:a novel synthetic surfactant for the treatment of respiratory distress syndrome

机译:Lucinactant:用于治疗呼吸窘迫综合征的新型合成表面活性剂

获取原文
获取原文并翻译 | 示例
       

摘要

Lucinactant (Surfaxin,Discovery Laboratories) is a synthetic surfactant,which contains the novel peptide,sinapultide,a surfactant-associated protein B mimic.Randomised clinical trials suggest that this compound is a safe and effective treatment for respiratory distress syndrome in preterm infants.It is also being actively investigated for other indications,including meconium aspiration syndrome,treatment of bronchopulmonary dysplasia in neonates,acute respiratory distress syndrome and asthma.A novel aerosol formulation administered with nasal continuous positive airway pressure is also under development for treatment of respiratory insufficiency in neonates.Its non-animal origin may make it an attractive alternative to present animal-derived surfactants by eliminating the risks of infection and immunogenicity related to the latter.
机译:Lucinactant(Surfaxin,Discovery Laboratories)是一种合成表面活性剂,其中包含新型肽,sinapultide,一种与表面活性剂相关的B蛋白模拟物。随机临床试验表明,该化合物是治疗早产儿呼吸窘迫综合征的安全有效方法。也正在积极研究其他适应症,包括胎粪吸入综合征,新生儿支气管肺发育不良,急性呼吸窘迫综合征和哮喘。正在开发一种鼻持续持续气道正压通气的新型气雾剂,用于治疗新生儿呼吸功能不全它的非动物来源可能消除感染的风险和与后者相关的免疫原性,从而使其成为目前动物源性表面活性剂的有吸引力的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号